Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
Aytu BioPharma 2024年第三季度GAAP每股收益美元（0.52美元）超過預期（0.64美元），銷售額1799.3萬美元超過預期的173.46億美元
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 73.06 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $17.993 million which beat the analyst consensus estimate of $17.346 million by 3.73 percent. This is a 20.85 percent decrease over sales of $22.733 million the same period last year.
艾圖生物製藥（納斯達克股票代碼：AYTU）公佈的季度虧損爲每股0.52美元，比分析師普遍預期的0.64美元（0.64美元）高出18.75％。與去年同期每股虧損1.93美元（1.93）相比，增長了73.06％。該公司公佈的季度銷售額爲1799.3萬美元，比分析師普遍預期的1734.6萬美元高出3.73％。這比去年同期的2,273.3萬美元的銷售額下降了20.85％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。